© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
May 23, 2019
Investigators presented information on the 9-month interim results of the ABX464-102 phase 2a examining efficacy in UC patients at DDW 2019.
May 21, 2019
Study from DDW 2019 found that rates of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and nonalcoholic cirrhosis was more than double in patients with UC.
A study presented at DDW 2019 found that endoscopic retrieval may help prevent further gastric damage from button battery ingestion.
May 20, 2019
A study presented at DDW 2019 found that women with intrahepatic cholestasis of pregnancy were 5.7 times more likely to have a NAFLD diagnosis
Study presented at DDW 2019 found that walking and resistance training was associated with a lower risk of cirrhosis-related death.
May 19, 2019
A study presented at DDW 2019 found that endoscopic sleeve gastroplasties found significant and sustainable weight loss among patients 5 years after surgery.
Study presented at DDW 2019 found that transplantation of gut microbes from lean donor could aid weight loss in obese, metabolically healthy recipients.
May 26, 2016
As medications for hepatitis C become more widely used, studies are being done to see how effective these treatments are when used in combination.
May 25, 2016
The development of new medications for any condition requires attention to detail in a number of areas, especially safety and efficacy. A recent drug developed for irritable bowel syndrome (IBS) looked to be effective in both areas prior to its approval.
Researchers reported that SVR12 rates in real-world, post-transplant genotype 1 HCV patients treated with ledipasvir-sofosbuvir, with or without ribavirin, is 98% across regimens and various characteristics.